This Notice was RESCINDED on November 19, 2020 by NOT-CA-21-016

RESCINDED

RESCINDED - Notice of Intent to Publish: Cellular Cancer Biology Imaging Research (CCBIR) Program (UM1 Clinical Trial Not Allowed)

Notice Number: NOT-CA-19-016

Key Dates

Release Date: January 03, 2019
Estimated Publication Date of Funding Opportunity Announcement: March 01, 2019
First Estimated Application Due Date: July 30, 2019
Earliest Estimated Award Date: April 01, 2020
Earliest Estimated Start Date: May 01, 2020

Related Announcements
NOT-CA-21-016

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites UM1 cooperative agreement applications for Cellular Cancer Biology Imaging Research (CCBIR) Programs. The cadre of CCBIR Programs created through this FOA will: 1) investigate fundamental cancer biology questions at subcellular to cellular length-scales in conjunction with development of advanced imaging technologies, and 2) foster a sustainable collaborative community that promotes synergies between basic cancer biology researchers and imaging technology developers.

This Notice is being provided to allow potential applicants sufficient time to develop a responsive, multicomponent CCBIR Program proposal. The FOA is expected to be published in March 2019 with an expected application due date in July 2019.

The FOA will utilize the UM1 (Research Project-Cooperative Agreements with Complex Structure) activity code to support large-scale research activities with a complicated structure that encompasses interdependent components and substantial Federal programmatic guidance. Details of the planned FOA are provided below.

Research Initiative Details

A successful CCBIR Program will create a resource environment where innovation in cellular imaging technologies is guided by the goal of addressing cancer biology problems in the focus area that defines the Program. Ideally, CCBIR Programs should be uniquely positioned to recognize cancer research problems that, 1) are solvable by the creation of innovative advanced cellular imaging approaches, and 2) have potential to either expand current concepts or create new fundamental lines of cancer research leveraging the imaging toolkit created over the award period.

CCBIR Program Organization

This FOA uses the multicomponent UM1 mechanism. Each CCBIR Program is comprised of three equivalent structural components: technology development (TECH), cancer biology research test-bed (RTB), and community engagement (CE).

The interdependent structure of each CCBIR Program fosters an iterative cycle of imaging technology development (TECH) that flows into the cancer biology research test-bed (RTB) of demonstration projects, which in turn motivates the next cycle of technical refinement and innovation. It is expected that the TECH developed in a CCBIR Program include a combination of instrumentation and other specialized devices, reagents, probes, software, and data handling methods collectively driven by the cancer biology question(s) under investigation in the RTB. A distinguishing characteristic of the CE component is a sizable budget reserve to support pilot projects solicited from the research community outside of the Program’s institutional base that collaboratively interface with the TECH and RTB components.

It is unlikely that a viable CCBIR Program would be formed de novo, rather CCBIR applicants would likely integrate and build off existing infrastructures in imaging, technology development, cell biology and cancer cell biology models toward addressing the central cancer biology topic of study. Some applicants may offer an arrangement where the putative CCBIR Program’s home institution provides additional complementary support in the form of allied cores, foundations, centers and/or institutes.

Funding Information

Estimated Total Funding $12,000,000 per year for five years of the CCBIR Program.
Expected Number of Awards The NCI intends to fund an estimate of 3 to 4 awards.
Estimated Award Ceiling TBD
Primary CFDA Numbers 93.393, 93.394, 93.395, 93.396, 93.399, 93.286

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
City or township governments
Special district governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Regional Organization

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Michael Graham Espey, Ph.D.
National Cancer Institute (NCI)
240-276-7619
SP@nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email:wolfreyc@mail.nih.gov